Business, energy, technology, markets and global industry news from Business News Today

AbbVie Inc.

PharmaDeviceNews AbbVie Inc.
A molecular illustration of antibody activity highlights argenx SE’s $2.2 billion acquisition of Forte Biosciences and the addition of investigational anti-CD122 antibody FB102 to its immunology pipeline. Representative image.
Pharma & Biotech

BIMZELX beat AbbVie’s US$5.8bn-a-quarter SKYRIZI on joint response. Why UCB still cannot claim broad superiority

BIMZELX sustained higher ACR50 than SKYRIZI at Week 24, but UCB’s statistical hierarchy limits broader superiority claims.

Read More
Representative image: CARVYKTI multiple myeloma treatment setting as Legend Biotech reports five-year progression-free survival after a single CAR T-cell infusion.
Pharma & Biotech

AbbVie submits FDA application for etentamig after Phase 3 CERVINO success in multiple myeloma

AbbVie seeks FDA approval for etentamig after Phase 3 myeloma results showed a 60% reduction in progression risk. Infection safety remains in focus.

Read More
Allergan Aesthetics’ European approval for Boey introduces a rapid-onset, short-duration neurotoxin option for treating moderate to severe frown lines. Representative image.
Pharma & Biotech

Boey can show results in hours and fade in weeks: Why AbbVie is betting shorter can be better

AbbVie wins European approval for Boey, a rapid-onset neurotoxin lasting two to three weeks, opening a new test of aesthetics demand.

Read More
Eli Lilly’s up to US$3.8 billion AtaiBeckley deal raises interest in BPL-003 and the expanding psychedelic medicine pipeline. Representative image.
Pharma & Biotech

Eli Lilly’s psychedelic deal carries a US$3.8bn headline, but the fine print tells the real story

Eli Lilly’s AtaiBeckley deal brings psychedelic medicine into big pharma’s M&A race, but Phase 3 data and rescheduling still decide its value.

Read More
REGENXBIO’s sura-vec gene therapy shows encouraging long-term durability in wet age-related macular degeneration and diabetic retinopathy. Representative image.
Pharma & Biotech

Can one gene therapy cut years of eye injections? REGENXBIO’s five-year data raise the stakes

REGENXBIO reports five-year wet AMD durability and 2.5-year diabetic retinopathy data as pivotal sura-vec milestones approach.

Read More
Representative image: Tepkinly’s European approval expands bispecific antibody treatment options for adults with relapsed or refractory follicular lymphoma, potentially reshaping second-line lymphoma care.
Pharma & Biotech

Genmab and AbbVie secure EU approval for Tepkinly in relapsed follicular lymphoma

Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.

Read More
Representative image of an oncology infusion setting as Genmab’s epcoritamab data raises hopes for new elderly DLBCL and diffuse large B-cell lymphoma treatment options.
Pharma & Biotech

Genmab pushes epcoritamab deeper into frontline lymphoma with elderly DLBCL data

Find out how Genmab’s epcoritamab data could reshape elderly DLBCL treatment as bispecific antibodies move into frontline care.

Read More
Pharma & Biotech

AbbVie Inc. secures strategic option on Kestrel Therapeutics Inc. amid KRAS innovation race

A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.

Read More
Pharma & Biotech

AbbVie’s fast-acting Botox rival just hit a regulatory wall, but not where investors feared

AbbVie’s TrenibotulinumtoxinE faces an FDA manufacturing CRL. Find out what this means for approval, aesthetics and neurotoxins.

Read More
Pharma & Biotech

Can a global trials map help fix spondyloarthritis’s fragmented development landscape?

Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.

Read More